Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.

Simple item page
dc.contributor.authorDickinson, Michael
dc.contributor.authorCherif, Honar
dc.contributor.authorFenaux, Pierre
dc.contributor.authorMittelman, Moshe
dc.contributor.authorVerma, Amit
dc.contributor.authorPortella, Maria Socorro O
dc.contributor.authorBurgess, Paul
dc.contributor.authorRamos, Pedro Marques
dc.contributor.authorChoi, Jeea
dc.contributor.authorPlatzbecker, Uwe
dc.contributor.authorSUPPORT study investigators
dc.date.accessioned2025-01-07T15:39:53Z
dc.date.available2025-01-07T15:39:53Z
dc.date.issued2018-10-10
dc.description.abstractAzacitidine treatment of myelodysplastic syndromes (MDSs) generally exacerbates thrombocytopenia during the first treatment cycles. A Study of Eltrombopag in Myelodysplastic Syndromes Receiving Azacitidine (SUPPORT), a phase 3, randomized, double-blind, placebo-controlled study, investigated the platelet supportive effects of eltrombopag given concomitantly with azacitidine. International Prognostic Scoring System intermediate-1, intermediate-2, or high-risk MDS patients with baseline platelets
dc.identifier.doi10.1182/blood-2018-06-855221
dc.identifier.essn1528-0020
dc.identifier.pmcPMC6337824
dc.identifier.pmid30305280
dc.identifier.unpaywallURLhttps://ashpublications.org/blood/article-pdf/132/25/2629/1746801/blood855221.pdf
dc.identifier.urihttps://hdl.handle.net/10668/27323
dc.issue.number25
dc.journal.titleBlood
dc.journal.titleabbreviationBlood
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.number2629-2638
dc.pubmedtypeClinical Trial, Phase III
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeRandomized Controlled Trial
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rights.accessRightsopen access
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAzacitidine
dc.subject.meshBenzoates
dc.subject.meshDouble-Blind Method
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshHydrazines
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshMyelodysplastic Syndromes
dc.subject.meshPlatelet Transfusion
dc.subject.meshPyrazoles
dc.subject.meshRisk Factors
dc.subject.meshThrombocytopenia
dc.titleAzacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number132

Files

Collections

SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía